Skip to main content

Polatuzumab vedotin Side Effects

Medically reviewed by Drugs.com. Last updated on Sep 8, 2023.

Applies to polatuzumab vedotin: intravenous powder for solution.

Serious side effects of Polatuzumab vedotin

Along with its needed effects, polatuzumab vedotin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking polatuzumab vedotin:

More common

Other side effects of Polatuzumab vedotin

Some side effects of polatuzumab vedotin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to polatuzumab vedotin: intravenous powder for injection.

Hematologic

Very common (10% or more): Neutropenia (49%), thrombocytopenia (49%), anemia (47%), lymphopenia (13%), febrile neutropenia (11%)

Common (1% to 10%): Pancytopenia[Ref]

Immunologic

Very common (10% or more): Infections (32%), herpesvirus infection (12%)

Common (1% to 10%): Cytomegalovirus infection

Uncommon (0.1% to 1%): Progressive multifocal leukoencephalopathy (PML), sepsis

Frequency not reported: Immunogenicity[Ref]

Local

Very common (10% or more): Infusion-related reactions (e.g., fever, chills, flushing, dyspnea, hypotension, urticaria) (67%)

Common (1% to 10%): Infusion-related reactions[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia[Ref]

Ocular

Common (1% to 10%): Blurred vision[Ref]

Metabolic

Very common (10% or more): Anorexia (27%), weight loss (16%), hypokalemia (16%), hypoalbuminemia (13%), hypocalcemia (11%)

Common (1% to 10%): Hypophosphatemia

Frequency not reported: Tumor lysis syndrome (TLS)[Ref]

Hepatic

Common (1% to 10%): Transaminase elevation[Ref]

Respiratory

Very common (10% or more): Dyspnea (19%), upper respiratory tract infection (16%), lower respiratory tract infection (10%)

Common (1% to 10%): Pneumonitis[Ref]

Other

Very common (10% or more): Pyrexia (33%)[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (40%), dizziness (13%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (38%), vomiting (18%)

Common (1% to 10%): Lipase increased[Ref]

References

1. Product Information. Polivy (polatuzumab vedotin). Genentech. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.